Infliximab was developed in the same TNF-inhibitor class as Adalimumab but takes an entirely different administration route — it's given exclusively as an IV infusion in a hospital or infusion-center setting, which means procurement decisions for this SKU depend on whether the receiving facility has infusion infrastructure in place, unlike its self-injectable counterpart. This makes it a distinctly hospital-oriented product line, complementary rather than competing with Adalimumab in a distributor's broader immunotherapy portfolio.
- Approved indications: Rheumatoid arthritis, Crohn's disease, ulcerative colitis, psoriatic arthritis, ankylosing spondylitis, plaque psoriasis
- Mechanism: Neutralizes TNF-alpha, similar to Adalimumab, but as a chimeric (part-mouse, part-human) antibody rather than fully human
- Administration: IV infusion only, typically given over 2+ hours in a hospital or dedicated infusion-center setting, with dosing at weeks 0, 2, 6, and then every 8 weeks thereafter
- Procurement consideration: Requires infusion-center infrastructure at the receiving facility — a key qualifying question for distributors before finalizing large orders
- Contraindication: Active TB or severe active infection
- Allergy note: Because it's part-mouse in origin, patients with known murine-protein allergy should not receive it
- Hepatitis B reactivation risk: Screening recommended before first infusion
- Breastfeeding: Delay recommended for 6 months following the final treatment
- Infusion reaction monitoring: Required during and immediately after each infusion given its chimeric antibody structure carries a somewhat higher immunogenicity profile than fully human biologics
- Certification: WHO-GMP sourced manufacturing
- Batch-specific testing: TNF-alpha neutralization activity validated per batch
- Infrastructure guidance: We confirm infusion-center capacity with new institutional buyers before finalizing bulk orders, to avoid stock sitting unused at facilities without infusion capability
| Document |
Included |
| Certificate of Analysis (COA) |
? Standard |
| Certificate of Origin (COO) |
? Standard |
| MSDS |
? Standard |
Stock status: In stock for export | Quote turnaround: 24 hours
- Logistics: GDP-compliant cold-chain export (2–8°C)
- Coverage: Global, primarily hospital-based distribution channels
- Tracking: Full shipment tracking included
- Institutional buyers: Hospital infusion-center procurement support
- Unregistered markets: Named-patient supply pathway available
- Portfolio positioning: Complements Adalimumab as the infusion-based option for facilities with infrastructure to support it
What is Infliximab used for?
Treats rheumatoid arthritis, Crohn's disease, ulcerative colitis, and psoriasis.
Get Infliximab price from a GMP-compliant Indian supplier — how?
Send strength and destination for a verified quote.
How is it administered?
Given only as an IV infusion in a hospital or dedicated infusion-center setting.
Who supplies Infliximab from India?
WHO-GMP certified manufacturer with full export documentation.
Can I get vaccines while on Infliximab?
Live vaccines should generally be avoided — discuss timing with the treating physician.
